Aarti Pharmalabs Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/e2ott5owgrcaxuk4ns9eqaey.pdf

Key Takeaways


Atali Plant: The Quarter's Central Problem

Gogri: "We have good visibility. Of course, we have to keep our finger crossed. We - our partners have to make sure that their launch drugs are being successful and they don't have any hiccups. So everything is contingent to how they are performing, post launch."

API Business: Volume Over Price

Gogri: "See, generic API business, the prices never increase. They always go down only. Ultimately, the game has to be played where you increase the capacity."

Xanthine: A Structural Tailwind in Early Innings

Gogri: "China has announced that they will withdraw the benefit - rebate benefit on caffeine and its salts. With that rebate withdrawal, overall 13% benefit that is getting accrued to the Chinese manufacturers when they export the API that will go away. And we are hoping that this will push the prices of the product up by at least 8% to 10% in future."

CDMO: Deferred, Not Derailed


Margins & Earnings: A Q4 Rebound Is Priced In


Guidance & Commitments

CommitmentSpecificsTimeline
Atali stabilizationStartup hiccups resolvedEnd of Q4 FY26
Xanthine expansion mechanical completion9,000 tonnes per annum capacity readyEnd of March 2026
Xanthine capacity utilizationReach 85-90% of 9,000-tonne capacityBy FY28
API quarterly run rateReach INR200 croresA couple more quarters
FY26 EBITDALargely in line with last year, marginal growthFY26 full year
FY26 CDMO revenueMeet guidance (exceeding now difficult)FY26 full year
CDMO growth rate30-40% range, similar to FY26FY27
CDMO customer countIncrease from current 21Calendar year 2026
Net debt to equity0.3-0.35x post all capexBy Q4 FY26
New CDMO block at AtaliAt least one block, not large capexFY27

Key Metrics

MetricQ3 FY26
Revenue₹425 cr, vs ₹471 cr a year back
EBITDA₹103 cr, vs ₹115 cr a year back
Profit after tax₹44 cr, vs ₹74 cr a year back
EBITDA margin24.2%, vs 24.4% a year back (per an analyst's math)
Gross debt₹650 cr (9 months ending)
Net debt~₹650 cr
Net debt to equity0.3 to 0.35 (post-capex target)
Interim dividend per share₹1.5
Xanthine Derivatives revenue share49% of turnover
Xanthine volume split63% beverages, 37% other
Xanthine geographical split51% export, 49% local sales
Xanthine operating run rate500 tonnes per month, adding 300 tonnes per month capacity; installed capacity ~9,000 tonnes per annum
API and Intermediates revenue share39% of turnover
API and Intermediates revenue~₹167 cr, vs ~₹180 cr a year back like-for-like, decline of 5-6%
API subsegment breakup52% regulated market, 34% ROW market, 14% non-reg market
CDMO/CMO revenue share12% of revenue
CDMO active projects59 total; 40 commercial stage, 19 under development
CDMO customers21
CDMO shipments (9M FY26)₹120-130 cr, plus ₹50 cr
Goods in transit (not booked as revenue)₹49 cr revenue value, ₹30 cr cost; PBT impact ₹19 cr
Atali plant capex₹300 cr capitalized of ₹450 cr total outlay
Atali monthly opex~₹1.5 cr
Xanthine total approved capex~₹150 cr (both sites)
CDMO sales target₹1,000 cr
Locked-in business percentage~50%